Hypera S.A. - ADR
HYPMY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.8B
Close$
$9.42
136.7% upside
Current Fair Value
136.7% upsideUndervalued by 136.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.80 Billion |
|---|---|
| Enterprise Value | $8.64 Billion |
| Annual dividend | $0.26 |
| Dividend yield | 4.89% |
| Earnings per Share | $1.89 |
| Beta | 0.11 |
| Outstanding Shares | 703,995,955 |
Return
| Return on Equity | 12.11% |
|---|---|
| Return on Assets | 5.98% |
| Return on Invested Capital | 9.87% |
Valuation & Multiples
| P/E Ratio | 8.19 |
|---|---|
| PEG | 57.2 |
| Price to Sales | 0.33 |
| Price to Book Ratio | 0.19 |
| Enterprise Value to Revenue | 0.96 |
| Enterprise Value to EBIT | 3.33 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.91 |
| Debt to Equity | 0.53 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 11, 2026
EPS
$0.15
Est. $0.14Revenue
$448.62 M
Est. $450.75 MNext Earnings Call
Expected Date
March 11, 2027
EPS Estimate
$0.13
Consensus analyst estimateRevenue Estimate
$451.81 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hypera S.A.
10,564 employees
CEO: Breno Toledo Pires de Oliveira
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Ci...